v3.26.1
Interim Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 563 $ 670
Restricted cash and restricted cash equivalents 0 2
Accounts and notes receivable, net 759 679
Inventories 1,536 1,569
Prepaid expenses and other 69 80
Assets held for sale 1 1
Total current assets 2,928 3,001
Property, plant, and equipment 9,925 9,920
Less: Accumulated depreciation (6,885) (6,842)
Property, plant, and equipment, net 3,040 3,078
Operating lease right-of-use assets 274 271
Goodwill 46 46
Other intangible assets, net 2 2
Investments in affiliates 166 160
Assets held for sale, non-current 21 21
Restricted cash and restricted cash equivalents 52 52
Other assets 738 751
Total assets 7,267 7,382
Current liabilities:    
Accounts payable 891 954
Compensation and other employee-related cost 122 96
Short-term and current maturities of long-term debt 37 42
Current environmental remediation 97 88
Other accrued liabilities 462 506
Total current liabilities 1,609 1,686
Long-term debt, net 4,100 4,099
Operating lease liabilities 192 191
Long-term environmental remediation 520 530
Deferred income taxes 40 37
Other liabilities 590 588
Total liabilities 7,051 7,131
Commitments and contingent liabilities
Equity    
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 199,180,562 shares issued and 150,355,228 shares outstanding at March 31, 2026; 198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025) 2 2
Treasury stock, at cost (48,825,334 shares at March 31, 2026 and 48,826,793 at December 31, 2025) (1,802) (1,802)
Additional paid-in capital 1,081 1,074
Retained earnings 1,178 1,220
Accumulated other comprehensive loss (244) (244)
Total Chemours stockholders’ equity 215 250
Non-controlling interests 1 1
Total equity 216 251
Total liabilities and equity $ 7,267 $ 7,382